<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004887.pub2" GROUP_ID="LIVER" ID="534303112509030808" MERGED_FROM="" MODIFIED="2012-02-14 15:25:56 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases</TITLE>
<CONTACT>
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Universidad de Carabobo and Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION>Edo. Carabobo</REGION>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1>+58 241 8712883</PHONE_1>
<PHONE_2/>
<FAX_1>+58 241 8712883</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Universidad de Carabobo and Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION>Edo. Carabobo</REGION>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1>+58 241 8712883</PHONE_1>
<PHONE_2/>
<FAX_1>+58 241 8712883</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="91074973891229674803100818162813" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Despoina-Elvira</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Karakitsiou</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>elvira-1989@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Ioannina Medical School</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Ioannina</CITY>
<ZIP>45500</ZIP>
<REGION/>
<COUNTRY CODE="GR">Greece</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17174" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Georgia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Salanti</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>georgia.salanti@googlemail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+30 6971863717</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Hygiene and Epidemiology</DEPARTMENT>
<ORGANISATION>University of Ioannina School of Medicine</ORGANISATION>
<ADDRESS_1>Medical School Campus</ADDRESS_1>
<ADDRESS_2>University of Ioannina</ADDRESS_2>
<CITY>Ioannina</CITY>
<ZIP>45110</ZIP>
<REGION/>
<COUNTRY CODE="GR">Greece</COUNTRY>
<PHONE_1>+30 26510 07757</PHONE_1>
<PHONE_2/>
<FAX_1>+30 26510 07853</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-01-30 13:43:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="27" MONTH="1" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="12" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="1" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-30 13:41:25 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-17 14:01:40 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="17" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>A new trial is added (<LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-01-30 13:41:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>The updated version includes two randomised clinical trials. The new trial strengthens but does not change the conclusions of the previous published review version.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-09 13:56:50 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2011-12-05 00:55:12 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2011-12-05 00:55:12 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2011-05-06 18:53:11 +0200" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2011-12-05 00:55:12 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Hepatobiliary Group</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-02-14 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-12-19 12:16:51 +0100" MODIFIED_BY="[Empty name]">Recombinant human activated factor VII for upper gastrointestinal bleeding in patients with liver diseases</TITLE>
<SUMMARY_BODY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>People with liver disease have an increased risk of upper gastrointestinal bleeding. Upper gastrointestinal bleeding is a frequent cause of morbidity and mortality in this population group. Due to severe liver damage, these people acquire coagulopathy (a bleeding disorder). Therefore, one of the approaches used for treating upper gastrointestinal bleeding is recombinant human activated factor VII, which is identical in structure and activity to human factor VII. The review includes two randomised clinical trials with 493 participants. The risk of bias was low. Both trials compared recombinant human activated factor VII with placebo. The meta-analysis showed that the recombinant human activated factor VII does not seem to reduce mortality in patients with liver disease and suffering from upper gastrointestinal bleeding, irrespective of the grade of liver damage. The current evidence is insufficient to support or reject recombinant human activated factor VII for these patients.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-02-14 14:06:07 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-12-19 12:11:28 +0100" MODIFIED_BY="[Empty name]">
<P>Mortality from upper gastrointestinal bleeding in patients with liver disease is high. Recombinant human activated factor VII (rHuFVIIa) has been suggested for patients with liver disease and upper gastrointestinal bleeding.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-09-16 19:20:24 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of rHuFVIIa in patients with liver disease and upper gastrointestinal bleeding.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register<I> </I>(December 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(Issue 4, 2011), MEDLINE (1948 to December 2011), EMBASE (1980 to December 2011), Science Citation Index Expanded (1900 to December 2011), and LILACS (December 2011). We sought additional randomised trials from the reference lists of the trials and reviews identified through the electronic searches.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-03-22 12:33:07 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome data from randomised clinical trials were extracted and were presented using random-effects model meta-analyses. Data on the risk of bias in the included trials were also extracted.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-02-14 14:06:07 +0100" MODIFIED_BY="[Empty name]">
<P>We included two trials with 493 randomised participants with various Child-Pugh scores. The trials had a low risk of bias. The rHuFVIIa administration did not reduce the risk of mortality within five days (21/288 (7.3%) versus 15/205 (7.3%); risk ratio (RR) 0.88, 95% confidence interval (CI) 0.48 to 1.64, I<SUP>2</SUP> = 49%) and within 42 days (5/286 (1.7%) versus 36/205 (17.6%); RR 1.01, 95% CI 0.55 to 1.87, I<SUP>2</SUP> = 55%) when compared with placebo. Trial sequential analysis demonstrated that there is sufficient evidence to exclude that rHuFVIIa decreases mortality by 80%, but there is insufficient evidence to exclude smaller effects. The rHuFVIIa did not increase the risk of adverse events by number of patients (218/297 (74%) and 164/210 (78%); RR 0.94, 95% CI 0.84 to 1.04, I<SUP>2</SUP> = 1%), serious adverse events by adverse events reported (164/590 (28%) versus 123/443 (28%); RR 0.91, 95% CI 0.75 to 1.11, I<SUP>2</SUP> = 0%), and thromboembolic adverse events (16/297 (5.4%) versus 14/210 (6.7%); RR 0.80, 95% CI 0.40 to 1.60, I<SUP>2</SUP> = 0%) when compared with placebo.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>We found no evidence to support or reject the administration of rHuFVIIa for patients with liver disease and upper gastrointestinal bleeding. Further adequately powered randomised clinical trials are needed in order to evaluate the proper role of rHuFVIIa for treating upper gastrointestinal bleeding in patients with liver disease. Although the results are based on trials with low risk of bias, the heterogeneity and the small sample size result in rather large confidence intervals that cannot exclude the possibility that the intervention has some beneficial or harmful effect. Further trials with alow risk of bias are required to make more confident conclusions about the effects of the intervention.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-02-14 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Upper gastrointestinal bleeding is the loss of blood affecting the alimentary canal from the mouth to the duodenum. Depending on the volume and speed of blood loss, upper gastrointestinal bleeding can lead to chronic anaemia or acute bleeding that may be life-threatening. Haematemesis (vomiting of blood) and melena (black, tarry faeces containing digested blood) are the most common symptoms and signs of upper gastrointestinal bleeding (<LINK REF="REF-Green-2003" TYPE="REFERENCE">Green 2003</LINK>). It is calculated that in France the yearly overall incidence of upper gastrointestinal bleeding is 143 patients per 100,000 persons (<LINK REF="REF-Czernichow-2000" TYPE="REFERENCE">Czernichow 2000</LINK>), whereas in the US it accounts for 100 patients per 100,000 persons per year. In the United Kingdom, the annual incidence of acute upper gastrointestinal bleeding ranges between 47 and 116 patients per 100,000 persons (<LINK REF="REF-Dallal-2001" TYPE="REFERENCE">Dallal 2001</LINK>).</P>
<P>Upper gastrointestinal bleeding is one of the most frequent causes of morbidity and mortality in the course of liver cirrhosis (<LINK REF="REF-Protell-1981" TYPE="REFERENCE">Protell 1981</LINK>; <LINK REF="REF-del-Olmo-2000" TYPE="REFERENCE">del Olmo 2000</LINK>). In patients in the advanced stages of cirrhotic liver disease, acute upper gastrointestinal bleeding is the most serious and life-threatening complication (<LINK REF="REF-Afessa-2000" TYPE="REFERENCE">Afessa 2000</LINK>). The causes of acute upper gastrointestinal bleeding in patients with cirrhotic liver disease are rupture of varices in the oesophagus, stomach, or in the duodenum; reflux oesophagitis; acute stomach mucosal lesions; peptic ulceration; and reduction in blood coagulation factors (<LINK REF="REF-Amitrano-2002" TYPE="REFERENCE">Amitrano 2002</LINK>; <LINK REF="REF-Green-2003" TYPE="REFERENCE">Green 2003</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Several treatments have been proposed for upper gastrointestinal bleeding in patients with liver disease. One of them is recombinant human activated factor VII (rHuFVIIa). It is manufactured by a recombinant DNA technique and is identical in structure and activity to human factor VII (<LINK REF="REF-Erhardtsen-2000" TYPE="REFERENCE">Erhardtsen 2000</LINK>). The rHuFVIIa enhances haemostasis at the site of injury, apparently without major systematic activation of the coagulation cascade (<LINK REF="REF-Erhardtsen-2002" TYPE="REFERENCE">Erhardtsen 2002</LINK>). The rHuFVIIa is, however, associated with thromboembolic adverse events (<LINK REF="REF-O_x0027_Connell--2006" TYPE="REFERENCE">O'Connell 2006</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>The rHuFVIIa directly activates factor X and increases thrombin production on the surface of activated platelets in the absence of factor VIII or IX, and also improves thrombin generation in thrombocytopenia (<LINK REF="REF-Allen-2002" TYPE="REFERENCE">Allen 2002</LINK>; <LINK REF="REF-Aitken-2004" TYPE="REFERENCE">Aitken 2004</LINK>; <LINK REF="REF-Franchini-2010" TYPE="REFERENCE">Franchini 2010</LINK>). Progressive loss of hepatocytes in patients with cirrhosis impairs synthesis of the vitamin K-dependent coagulation factors, producing a deficiency in factor VII levels and prolongation of prothrombin times (<LINK REF="REF-Paramo-1993" TYPE="REFERENCE">Paramo 1993</LINK>). Studies have shown that rHuFVIIa reduces prolonged prothrombin time in adult non-bleeding patients with cirrhosis (<LINK REF="REF-Bernstein-1997" TYPE="REFERENCE">Bernstein 1997</LINK>; <LINK REF="REF-Van-Thiel-2005" TYPE="REFERENCE">Van Thiel 2005</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-01-17 14:13:34 +0100" MODIFIED_BY="[Empty name]">
<P>We were unable to find a systematic review or meta-analyses assessing recombinant human activated factor VII (rHuFVIIa) for patients with liver diseases and upper gastrointestinal bleeding.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of the recombinant human activated factor VII (rHuFVIIa) in patients with liver disease and upper gastrointestinal bleeding.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-02-14 14:07:35 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials, irrespective of trial design, publication status (unpublished or published as an article, abstract or letter), and language. Data from quasi-randomised or observational studies that came up in the searches for randomised trials were included for assessment of harm but not for benefit.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients of all ages with liver disease and upper gastrointestinal bleeding, irrespectively of aetiology. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Recombinant human activated factor VII at any dosage and for any duration of treatment versus placebo or any other control intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>1. Mortality.<BR/>2. Adverse events. We have defined serious adverse events according to the International Conference on Harmonisation (ICH) Guidelines (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>), as any event that leads to death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability. All other adverse events have been considered as non-serious.<BR/>3. Quality of life, as measured by any scale.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>4. Number of patients transfused<BR/>5. Number of packed red cell transfusions</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-02-14 14:07:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ELECTRONIC_SEARCHES MODIFIED="2012-02-14 14:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (<LINK REF="REF-Gluud-2011" TYPE="REFERENCE">Gluud 2011</LINK>), the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>, MEDLINE, EMBASE, Science Citation Index Expanded, and LILACS (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>). We searched the databases using the search strategies and time spans given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We also checked the reference lists of all the trials identified by the above methods. In addition, we searched trial registries via the World Health Organization International Clinical Trials Registry Platform search portal (<A HREF="http://apps.who.int/trialsearch/Default.aspx">ICTRP</A>). We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2011-12-04 16:50:28 +0100" MODIFIED_BY="[Empty name]">
<P>Arturo Martí-Carvajal (AMC) and Despoina-Elvira Karakitsiou (DEK) screened the search results for potentially relevant trials and independently assessed them for inclusion or exclusion, using a pre-designed eligibility form based on the inclusion criteria. We solved disagreements through discussion until consensus was reached.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Georgia Salanti (GS) designed a standard data extraction form and AMC validated it. Two authors (AMC and DEK) used this form to extract data from each relevant trial. The two authors independently extracted information from the trial publications and contacted authors of the included trials for information that was lacking. AMC and DEK extracted information on the study design and patient characteristics (age, sex, and disease severity as measured by the Child-Pugh score). DEK calculated results based on an<I> </I>intention-to-treat analysis (ITT). When this was not possible, we used available patient information analysis.</P>
<P>AMC entered the data into Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>), and DEK and GS checked the data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the following domains (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>):</P>
<SUBSECTION>
<HEADING LEVEL="5">Generation of allocation sequence (checking for possible selection bias)</HEADING>
<P>We described for each included trial the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI>low risk (any truly random process, eg, random number table; computer random number generator);</LI>
<LI>high risk (any non-random process, eg, odd or even date of birth; hospital or clinic record number);</LI>
<LI>unclear, if the trial was described as randomised but the method used for the allocation sequence generation was not described.   </LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included trial the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocation could have been foreseen, in advance of or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk (eg, telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth);</LI>
<LI>unclear, if the trial was described as randomised but the method used to conceal the allocation was not described.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blinding or masking (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We judged trials at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results. We assessed blinding separately for different outcomes or classes of outcomes.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk, high risk, or unclear for participants;</LI>
<LI>low risk, high risk, or unclear for personnel;</LI>
<LI>low risk, high risk, or unclear for outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<UL>
<LI>Low risk (any one of the following): no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</LI>
</UL>
<UL>
<LI>High risk (any one of the following): reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</LI>
</UL>
<UL>
<LI>Unclear risk (any one of the following): insufficient reporting of attrition or exclusions to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217; (eg, number randomised not stated, no reasons for missing data provided); the study did not address this outcome.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Selective reporting bias (reporting bias due to selective outcome reporting)</HEADING>
<P>We described for each included trial how we investigated the possibility of selective outcome reporting bias and what we found.</P>
<P>We assessed the methods as follows.</P>
<UL>
<LI>Low risk (any one of the following): the trial protocol is available and all of the trial&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way, or the trial protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</LI>
</UL>
<UL>
<LI>High risk (any one of the following): not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (eg, subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the trial report fails to include results for a key outcome that would be expected to have been reported for such a trial.</LI>
</UL>
<UL>
<LI>Unclear: insufficient information to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217;.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Free of other bias (bias due to problems not covered elsewhere in the table)</HEADING>
<P>We described for each included trial any important concerns we have about other possible sources of bias (baseline imbalance, sponsorship bias, confirmation bias, bias of the presentation data, etc).</P>
<UL>
<LI>low risk of bias, the trial appears to be free of other components that could put it at risk of bias;</LI>
<LI>unclear, the trial may or may not be free of other components that could put it at risk of bias;</LI>
<LI>high risk of bias, there are other factors in the trial that could put it at risk of bias, eg, no sample size calculation made.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Overall risk of bias</HEADING>
<P>We made explicit judgements about whether trials were at high risk of bias, according to the criteria given in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We assessed the likely magnitude and direction of bias, and whether we considered it likely to impact our findings. </P>
<P>Trials assessed as having 'low risk of bias' in all of the above specified individual domains were considered as 'trials with low risk of bias'. Trials assessed as having 'uncertain risk of bias' or 'high risk of bias' in one or more of the above specified individual domains were considered as trials with 'high risk of bias' (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Data analyses</HEADING>
<P>We performed the meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2011" TYPE="REFERENCE">Gluud 2011</LINK>). Review Manager 5 was used to analyse the data (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). For binary outcome measures (mortality and adverse events), we calculated the risk ratios (RR) with 95% confidence intervals (CIs). The number of packed red cell transfusions was reported as a continuous outcome in both randomised trials; however it did not seem to follow a normal distribution as the original reports presented results using non-parametric statistics. For this outcome, the results were presented separately for each trial.<BR/>
</P>
<P>If trials reporting continuous data for which a normal distribution can be assumed are identified in the future, we will use the mean difference or the standardised mean difference if different scales are reported across the trials.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-05-06 18:28:56 +0200" MODIFIED_BY="[Empty name]">
<P>Aggregate data from comparison groups of randomised clinical trials.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>We contacted the main author of each randomised trial in an attempt to obtain information on missing data. As no further information was provided, we carried out an available patient information analysis as our main analysis, that is, the denominator for each outcome in each trial was the number randomised minus the number of participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-01-17 14:23:05 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We used the I<SUP>2 </SUP>statistic and the Q test to measure statistical heterogeneity between the trials. I<SUP>2</SUP>
<B> </B>describes the percentage of total variation between trials due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>For future updates, if we are able to include at least 10 randomised trials in a single meta-analysis, we will assess whether the review is subject to possible bias by using a funnel plot. The funnel plot illustrates the association between precision and effect size, and asymmetry can be due to several reasons including genuine heterogeneity and differences in the risk of bias between small and large trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We used both fixed-effect and random-effects models to combine the data. We reported only the results from the random-effects model when the confidence interval comprised the confidence interval from the fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>For future updates, we will perform subgroup analysis by analysing patients with cirrhosis and liver transplantation in separate analyses. We will also perform subgroup analysis by disease severity using Child-Pugh's classification (grades A, B, and C), by age, and participant's sex.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>We repeated the meta-analysis of the primary outcome according to the best-case scenario for lost participants (assuming that all lost participants in the treatment group had a positive outcome, and all lost participants in the control group died) and the worst-case scenario (all lost participants in the treatment group died and all lost participants in the control group were alive).</P>
<P>We conducted a sensitivity analysis to exclude a very large intervention effect of 80%, also 60%, 40%, and 30% relative risk reduction (RRR) of mortality within five days from the two included randomised trials. It was performed with Trial Sequential Analysis (TSA) (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>) (http://ctu.dk/tsa).</P>
<SUBSECTION>
<HEADING LEVEL="4">Summary of findings tables</HEADING>
<P>We used the principles of the GRADE system in our review (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) to assess the quality of the body of evidence associated with specific outcomes, that is, mortality and adverse events, and to construct a summary of findings (SoF) table using the GRADEpro software. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The evaluation takes into account the risk of bias, the directness of the evidence, the heterogeneity, the precision in summary effect estimates, and the risk of publication bias.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-02-14 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, the search strategy yielded a further 232 hits. Out of them, we identified 14 potentially relevant publications. We excluded 11 publications as they did not meet our inclusion criteria (see table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> was already included in the first version of our review. The remaining reference on a trial, also by <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>, met the inclusion criteria. Therefore, this updated Cochrane review includes two randomised trials (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the flowchart of the search result.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> included patients with all Child-Pugh scores, whereas <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> only included patients with a Child-Pugh score more than eight (advanced cirrhosis). The trial by <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> was conducted in Europe, whereas the trial by <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> was performed in Europe and Asia. <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> used rHuFVIIa at 100 µg/kg versus placebo. <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> was conducted using two doses of rHuFVIIa, 600 µg/kg and 300 µg/kg, versus placebo.</P>
<P>Both randomised trials used a single participant as the unit of randomisation (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). The trials were conducted using a parallel-study design. Both trials had primary composite outcomes including the following outcome measures: control of acute bleeding, prevention of rebleeding, and mortality over the five-day trial period. <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> included two groups for comparison, and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> included three groups.<BR/>
</P>
<P>Each randomised trial was conducted with less than 300 participants. <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> included 245 participants and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> had 265 participants. <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> was conducted between April 2001 to April 2002, and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> was conducted between April 2004 to August 2006. The trial intervention period in days for both randomised trials was five days. <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> had a final follow-up period of 42 days.</P>
<P>Further details are shown in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies were excluded (<LINK REF="STD-Ejlersen-2001" TYPE="STUDY">Ejlersen 2001</LINK>; <LINK REF="STD-Plessier--2004" TYPE="STUDY">Plessier 2004</LINK>; <LINK REF="STD-Romero_x002d_Castro-2004" TYPE="STUDY">Romero-Castro 2004</LINK>; <LINK REF="STD-Bosch-2005" TYPE="STUDY">Bosch 2005</LINK>; <LINK REF="STD-Vilstrup-2006" TYPE="STUDY">Vilstrup 2006</LINK>; <LINK REF="STD-Mart_x00ed__x002d_Carvajal-2007" TYPE="STUDY">Martí-Carvajal 2007</LINK>; <LINK REF="STD-Franchini-2008" TYPE="STUDY">Franchini 2008</LINK>; <LINK REF="STD-Flower-2010" TYPE="STUDY">Flower 2010</LINK>; <LINK REF="STD-Levi-2010" TYPE="STUDY">Levi 2010</LINK>; <LINK REF="STD-Arellano_x002d_Rodrigo-2011" TYPE="STUDY">Arellano-Rodrigo 2011</LINK>; <LINK REF="STD-Thabut-2011" TYPE="STUDY">Thabut 2011</LINK>). See the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table for a detailed account of the reasons for exclusion.<BR/>
</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias of <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> is summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The risk of bias was considered low.<BR/>
</P>
<ALLOCATION MODIFIED="2011-03-22 14:33:01 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Both randomised trials had adequate generation of allocation sequence and adequate allocation concealment (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-05-09 18:04:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> had adequate blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Both included trials had adequate reporting of outcome data (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>), and the few losses to follow-up were not expected to bias the result.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-03-22 14:34:29 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Both included trials had adequate reporting of the primary outcome (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>).</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-02-14 14:08:30 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>1.1. Death within five days (2 randomised trials; 493 participants; 36 deaths).<BR/>The risk ratio (RR) for mortality within five days was statistically non-significant (RR 0.95, 95% CI 0.36 to 2.50; P = 0.16, I<SUP>2</SUP> = 49%) (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). See <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>. The heterogeneity was moderate (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>Death within 42 days (2 randomised trials; 491 participants; 91 deaths).<BR/>The RR for mortality within 42 days did not reveal any significant benefit of rHuFVIIa compared with placebo (RR 1.01, 95% CI 0.55 to 1.87; P = 0.14, I<SUP>2</SUP> = 55%) (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). See <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.<BR/>
</P>
<P>Sensitivity analyses of mortality to account for losses to follow-up did not challenge the main conclusions. The summary RRs for the worst-case scenario and the best-case scenario were RR 1.37 (95% CI 0.52 to 3.58) for deaths within 5 days and RR 1.25 (95% CI 0.61 to 2.59) for deaths within 42 days; and RR 0.70 (95% CI 0.31 to 1.54) for deaths within 5 days and RR 0.91 (95% CI 0.49 to 1.68) for deaths within 42 days, respectively. See '<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> and <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> for the worst-case scenario and <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> and <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> for the best-case scenario.</P>
<P>Sensitivity analyses to exclude a very large intervention effect of 80%, and 60%, 40%, and 30% RRR of mortality within five days from the two included randomised trials showed that we can exclude a very large intervention effect of 80% RRR of deaths within five days from the two included trials (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). However, we are unable to exclude RRR intervention effects of 60%, 40%, 30% (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), and below (data not shown). For such smaller intervention effects the number of trial participants has to be increased substantially.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Two randomised trials; 507 participants; 382 participants with at least one event.<BR/>The risk ratio (RR) for overall incidence of adverse events was statistically non-significant comparing rHuFVIIa with placebo (RR 0.94, 95% CI 0.84 to 1.04; P = 0.20, I<SUP>2</SUP> = 1%) (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). See <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.<BR/>
<BR/>Serious adverse events by total adverse events (2 randomised trials; 1043 total adverse events, 287 serious adverse events).<BR/>The RR for serious events was statistically non-significant comparing rHuFVIIa with placebo (RR 0.90, 95% CI 0.73 to 1.09; P = 0.20, I<SUP>2</SUP> = 0%) (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). See <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.<BR/>
<BR/>Thromboembolic adverse events by participants (2 randomised trials; 507 participants; 30 thromboembolic events).<BR/>The RR for thromboembolic events was statistically non-significant comparing rHuFVIIa with placebo (RR 0.80, 95% CI 0.40 to 1.60; P = 0.20, I<SUP>2</SUP> = 0%) (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). See <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>This outcome was not reported in either of the trials (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>; <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). Although the two trials had an overall relatively low risk of bias, the number of events and number of included patients were small, leaving room for play of chance. As demonstrated in the trial sequential analysis, we were able to exclude a dramatic 80% RRR. However, the other trial sequential analyses demonstrated that we still have insufficient evidence to exclude or prove smaller, still clinically relevant, intervention effects.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<P>1. Number of patients with blood transfusion.<BR/>This outcome was not reported, neither in <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> nor <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>.</P>
<P>2. Number of packed red cell transfusions.<BR/>
<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> found no significant difference in packed red blood cell transfusion needs; P values for comparing red blood cell requirements between the two groups within 24 hours and within five days were 0.51 and 0.73 (based on Wilcoxon test), respectively.</P>
<P>
<LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> found no significant difference in packed red blood cell transfusion needs; P values for comparing red blood cell requirements between the three groups for the trend within 24 hours and within five days were 0.11 and 0.30 (based on Jonckheere-Terpstra test), respectively.</P>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis, sensitivity analysis, and assessment of reporting bias</HEADING>
<P>As only two trials were identified, no further subgroup or sensitivity analyses were carried out as initially planned. For the same reason, no funnel plot was drawn.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Two randomised trials are included in this updated review of rHuFVIIa for treating upper gastrointestinal bleeding in patients with liver disease at various stages (according to the Child-Pugh score). This critical appraisal of the trials neither supports nor rejects the use of rHuFVIIa. We did not find any significant differences in incidence of death within five and 42 days between rHuFVIIa and placebo. The data from the included trials (493 participants) are fairly consistent.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> could not confirm the beneficial effect of rHuFVIIa in cirrhotic patients as suggested by two previous studies (<LINK REF="REF-Brown-2003" TYPE="REFERENCE">Brown 2003</LINK>; <LINK REF="REF-Tonda-2003" TYPE="REFERENCE">Tonda 2003</LINK>). We believe that the conclusions from these randomised trials are not very likely to be biased. If any bias is likely to be present, this would probably be associated with the funding source; funding from the manufacturing pharmaceutical company is expected to be associated with a positive result. <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> failed to reject the null hypothesis of no significant difference between rHuFVIIa and placebo.</P>
<P>When dealing with such neutral results, we need to keep in mind that 'absence of evidence' is not 'evidence of absence' (<LINK REF="REF-Altman-1995" TYPE="REFERENCE">Altman 1995</LINK>; <LINK REF="REF-Fermi-Paradox" TYPE="REFERENCE">Fermi Paradox</LINK>). The fact that this review did not detect any differences between the two intervention groups does not imply that placebo and rHuFVIIa have the same mortality risk. The first possible explanation is failure to determine an appropriate sample size (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Green-2002" TYPE="REFERENCE">Green 2002</LINK>). In a remarkable paper done 28 years ago, Freiman et al suggested that "many of the therapies labelled as 'no different from control' in trials using inadequate samples, have not received a fair test" and that "concern for the probability of missing an important therapeutic improvement because of small sample sizes deserves more attention in the planning of clinical trials" (<LINK REF="REF-Freiman-1978" TYPE="REFERENCE">Freiman 1978</LINK>). In 1994, Moher et al emphasised that "most trials with negative results did not have large enough sample sizes to detect a 25% or a 50% relative difference" (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). Moreover, it had been suggested that the most important therapies adopted in clinical practice have shown more modest benefits (<LINK REF="REF-Kirby-2002" TYPE="REFERENCE">Kirby 2002</LINK>). Whereas the trials by <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> were adequately powered to detect differences in the composite outcome (See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>), they did not have enough power to detect differences in mortality. <LINK REF="STD-Mart_x00ed__x002d_Carvajal-2007" TYPE="STUDY">Martí-Carvajal 2007</LINK> et al pointed out "if rHuFVIIa has a small effect on mortality, it is possible that the trial by <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> et al was not powered enough to detect it". This statement is also applicable for <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>. Sample size in <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> was 245 participants, and 265 in <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>. However, both randomised trials expected to detect a 50% RRR.</P>
<P>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK> show that <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> seem to have overoptimistic considerations about which intervention effect they could prove or disprove and that the drug could still have an effect that would not only be statistically significant but also clinically significant. Even a 5% or 10% reduction of mortality within five days would be meaningful. However, it would take much larger trials to prove or disprove such effects.</P>
<P>A further possibility is that rHuFVIIa does not have the beneficial effect that we initially thought because, as suggested by Tripodi et al, bleeding events are mainly due to haemodynamic alterations secondary to portal hypertension and not due to the derangement of coagulation (<LINK REF="REF-Tripodi-2005" TYPE="REFERENCE">Tripodi 2005</LINK>).</P>
<P>
<LINK REF="STD-Mart_x00ed__x002d_Carvajal-2007" TYPE="STUDY">Martí-Carvajal 2007</LINK> et al stated that "...Bosch et al (<LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>) failed to reject the null hypothesis even for the composite outcome. The only statistically significant result that they found was among patients with more severe liver disease; patients with Child-Pugh score of B or C seem to benefit from rHuFVIIa administration. Therefore, a further possible explanation for the overall negative result could be the association of the effectiveness of the drug with the baseline risk. Again, this hypothesis based on a sub-group analysis should be investigated in adequately powered trials". Indeed, the <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> trial was conducted for testing the efficacy and safety of rHuFVIIa in patients with severe liver disease (Child-Pugh score more than 8 points); however, <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> failed to reject the null hypothesis even for the composite outcome in this high risk population at any dose of rHuFVIIa, either 600 &#956;g/kg or 300 &#956;g/kg. This supports the conclusion that rHuFVIIa does not work for treating upper gastrointestinal bleeding in patients with liver diseases.</P>
<P>
<LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> shows that rHuFVIIa "42-day mortality was significantly lower with 600 &#956;g/kg compared with placebo". However, this trial was not designed for assessing that hypothesis. This review shows an increase of 55% (95% CI 9% to 120%) at 42-day mortality in the intervention group. This is emphasised with a reduction of 95% CI (improvement of precision) when data from <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> were pooled. Furthermore, <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> pointed out that "bleeding-related deaths were reduced from 12% (placebo) to 2% (600 &#956;g/kg)"; but, overall, there was no significant difference between placebo and rHuFVIIa on this outcome (RR 0.51, 95% CI 0.22 to 1.17). This could be considered as 'SPIN' ("specific reporting strategies, whatever their motive, to highlight that the experimental treatment is beneficial, despite a statistically non-significant difference for the primary outcome, or to distract the reader from statistically non-significant result") (<LINK REF="REF-Boutron-2010" TYPE="REFERENCE">Boutron 2010</LINK>). Unfortunately, we were not able to pool data on cause of death at 42 days because it was not supplied by <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK>.<BR/>
</P>
<P>What could be the value of these neutral results? Neutral and negative results should be viewed as positives: "If non-significant results remain unpublished, we will be left with only half the picture" (<LINK REF="REF-O_x0027_Hara-2006" TYPE="REFERENCE">O'Hara 2006</LINK>). At least three papers suggest the importance of paying attention to 'negative' randomised clinical trials (<LINK REF="REF-Hebert-2002" TYPE="REFERENCE">Hebert 2002</LINK>; <LINK REF="REF-NERI-2003" TYPE="REFERENCE">NERI 2003</LINK>; <LINK REF="REF-Silva-de-Lima-2004" TYPE="REFERENCE">Silva de Lima 2004</LINK>). We should consider such a 'negative' result from a multifaceted perspective.</P>
<P>We need to consider the cost of administration of rHuFVIIa. <LINK REF="REF-Aitken-2004" TYPE="REFERENCE">Aitken 2004</LINK> had pointed out "The wholesale cost of a 2.4 mg vial of rFVIIa in Australia is $A2257.50 (Euros 1,840.75/ US$2,232.55)... Based on a 70 kg person, using 90 &#956;g/kg to 110 &#956;g/kg dosing, the cost per dose ranges from $A5926 (Euros 4,830.12 / US$ 6,125.12)... With most off-label uses requiring 2 to 3 doses, the average cost per patient would be a minimum of $A12 000 to 15 000 (Euros 14,490.36 / US$ 18,375.36) or...". Furthermore, rHuFVIIa might be associated with thromboembolic events (<LINK REF="REF-Pavese-2005" TYPE="REFERENCE">Pavese 2005</LINK>; <LINK REF="REF-O_x0027_Connell--2006" TYPE="REFERENCE">O'Connell 2006</LINK>; <LINK REF="STD-Levi-2010" TYPE="STUDY">Levi 2010</LINK>; <LINK REF="STD-Arellano_x002d_Rodrigo-2011" TYPE="STUDY">Arellano-Rodrigo 2011</LINK>; <LINK REF="STD-Thabut-2011" TYPE="STUDY">Thabut 2011</LINK>). However, this updated review found no significant differences in the safety of rHuFVIIa when compared with placebo.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> shows the quality of evidence for rHuFVIIa compared with placebo in treating patients with upper gastrointestinal bleeding associated with liver diseases.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>In a systematic review process, there is a group of biases called significance-chasing biases (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>), which include publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, this Cochrane review has a low risk of publication bias due to the meticulous trial search. Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to study publication bias in that &#8216;negative&#8217; results remain unpublished (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). This Cochrane review found that both included randomised trials have low risk of attrition bias and low risk of selective outcome reporting.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> concluded that the "decision on the use of this haemostatic agent in acute variceal bleeding should be carefully considered, because results of this trial do not support the routine use of rHuFVIIa in this setting". The findings of this Cochrane review are in agreement with <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>This Cochrane review provides evidence that rHuFVIIa does not seem to reduce mortality in patients with liver diseases complicated by upper gastrointestinal bleeding. The results are based on two low risk of bias trials with 493 patients that assessed rHuFVIIa compared with placebo. The included trials did not show a benefit in preventing mortality in patients at any Child-Pugh score. Therefore, prescription of this intervention for treating patients with liver diseases suffering from upper gastrointestinal bleeding can neither be supported nor rejected, unless new evidence from a large high-quality trial alters this conclusion.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-05-09 18:03:43 +0200" MODIFIED_BY="[Empty name]">
<P>Further adequately powered randomised clinical trials are necessary in order to evaluate the proper role of rHuFVIIa for treating upper gastrointestinal bleeding in patients with liver disease.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-14 20:01:20 +0100" MODIFIED_BY="[Empty name]">
<P>GS was supported by an European Research Council (ERC) Starting Grant (IMMA 260559).</P>
<P>We want to express our gratitude to Dimitrinka Nikolova for improving the quality of this review. We thank Christian Gluud for conducting and interpreting the trial sequential analyses.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-03-22 17:48:09 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>In 2004, Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>In 2007, Arturo Martí-Carvajal was employed by Merck to run a four-hour workshop 'How to critically appraise clinical trials and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>Georgia Salanti and Despoina-Elvira Karakitsiou do not have any conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-01-14 20:01:46 +0100" MODIFIED_BY="[Empty name]">
<P>Arturo Marti-Carvajal took the lead on writing up the protocol and the review, and acts as guarantor of the review.<BR/>
<BR/>Georgia Salanti and Despina-Elvira Karakitisiou joined the review authors at the review stage. They both extracted data, carried out most of the statistical analyses, drafted parts of the review, and revised the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Differences between the last version of the review </B>(<LINK REF="STD-Mart_x00ed__x002d_Carvajal-2007" TYPE="STUDY">Martí-Carvajal 2007</LINK>) <B>and the present updated version of the review</B>
<BR/>
</P>
<OL>
<LI>Summary of findings table was included.</LI>
<LI>In the previous version (<LINK REF="STD-Mart_x00ed__x002d_Carvajal-2007" TYPE="STUDY">Martí-Carvajal 2007</LINK>), we searched the databases until 2005. In this updated version, we have rerun the searches until October 2010.</LI>
<LI>We have found one new randomised trial that met our inclusion criteria (<LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK>). This trial strengthens but does not change the conclusions of the review. Thus, the included trials are now two.</LI>
<LI>We activated new subheadings in the Background, Methods, and Discussion sections.</LI>
<LI>We incorporated risk of bias (RoB) and summary of findings tables (SoF).</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality is the primary outcome in the protocol for this systematic review. However, this outcome was analysed in <LINK REF="STD-Bosch-2004" TYPE="STUDY">Bosch 2004</LINK> and <LINK REF="STD-Bosch-2008" TYPE="STUDY">Bosch 2008</LINK> as 'deaths within five days and deaths within 42 days', and it was one of the three components of the primary composite outcome. So, we decided to report on it in separate analyses.</P>
<P>We incorporated risk of bias (ROB) and summary of findings tables (SOF).</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bosch-2004" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Bosch 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-12-20 13:12:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez Abraldes J, et al</AU>
<TI>Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>1123-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thabut D, de Franchis R, Bendtsen F, D'Amico G, Albillos A, Abraldes JG, et al</AU>
<TI>Efficacy of activated recombinant factor VII (RFVIIA; Novoseven®) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38 Suppl 2</VL>
<PG>13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosch-2008" MODIFIED="2011-05-09 17:34:08 +0200" MODIFIED_BY="[Empty name]" NAME="Bosch 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-05-09 17:34:08 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J; International Study Group on rFVIIa in UGI Hemorrhage</AU>
<TI>Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial</TI>
<SO>Hepatology</SO>
<YR>2008</YR>
<VL>47</VL>
<PG>1604-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arellano_x002d_Rodrigo-2011" MODIFIED="2012-01-16 17:34:16 +0100" MODIFIED_BY="[Empty name]" NAME="Arellano-Rodrigo 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-01-16 17:34:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Arellano-Rodrigo E</AU>
<TI>Safety of recombinant activated factor VII in randomized clinical trials</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>364</VL>
<NO>6</NO>
<PG>574-5; author reply 575-6</PG>
<IDENTIFIERS MODIFIED="2012-01-16 17:34:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosch-2005" MODIFIED="2010-07-07 12:32:44 +0200" MODIFIED_BY="[Empty name]" NAME="Bosch 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-07-07 12:32:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosch J, Thabut D, Bendtsen F, Russo MW</AU>
<TI>Factor VIIA for upper GI bleeding in cirrhotic patients: It is all in the study design</TI>
<SO>Evidence-Based Gastroenterology</SO>
<YR>205</YR>
<VL>6</VL>
<PG>22-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ejlersen-2001" NAME="Ejlersen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H</AU>
<TI>Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>36</VL>
<PG>1081-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flower-2010" MODIFIED="2011-12-20 13:13:30 +0100" MODIFIED_BY="[Empty name]" NAME="Flower 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-20 13:13:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flower O, Phillips LE, Cameron P, Gunn K, Dunkley S, Watts A, et al</AU>
<TI>Recombinant activated factor VII in liver patients: a retrospective cohort study from Australia and New Zealand</TI>
<SO>Blood Coagulation &amp; Fibrinolysis</SO>
<YR>2010</YR>
<VL>21</VL>
<PG>207-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franchini-2008" MODIFIED="2010-07-07 12:36:49 +0200" MODIFIED_BY="[Empty name]" NAME="Franchini 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-07-07 12:36:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franchini M, Montagnana M, Targher G, Zaffanello M, Lippi G</AU>
<TI>The use of recombinant factor VIIa in liver diseases</TI>
<SO>Blood Coagulation &amp; Fibrinolysis</SO>
<YR>2008</YR>
<VL>19</VL>
<PG>341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-2010" MODIFIED="2012-01-16 17:34:32 +0100" MODIFIED_BY="[Empty name]" NAME="Levi 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-01-16 17:34:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, Levy JH, Andersen HF, Truloff D</AU>
<TI>Safety of recombinant activated factor VII in randomized clinical trials</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>19</NO>
<PG>1791-800</PG>
<IDENTIFIERS MODIFIED="2012-01-16 17:34:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mart_x00ed__x002d_Carvajal-2007" MODIFIED="2011-05-19 17:27:41 +0200" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-05-19 17:27:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Marti-Carvajal AJ, Salanti G, Marti-Carvajal PI</AU>
<TI>Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-05-19 17:27:35 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-05-19 17:27:35 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004887.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plessier--2004" NAME="Plessier  2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plessier A</AU>
<TI>Evaluation and non-specific management of upper gastrointestinal bleeding due to rupture of esophageal varices</TI>
<TO>Évaluation et prise en charge non spécifique de l'hémorragie digestive par rupture de varices oesophagiennes</TO>
<SO>Gastroentérologie Clinique et Biologique</SO>
<YR>2004</YR>
<VL>28</VL>
<PG>B9-B14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romero_x002d_Castro-2004" NAME="Romero-Castro 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, Gomez-Parra M, Arguelles Arias F, Guerrero-Aznar MD, et al</AU>
<TI>Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices</TI>
<SO>Clinical Gastroenterology and Hepatology</SO>
<YR>2004</YR>
<VL>2</VL>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thabut-2011" MODIFIED="2012-01-16 17:35:01 +0100" MODIFIED_BY="[Empty name]" NAME="Thabut 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-01-16 17:35:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thabut D, Rudler M, Rousseau G, Poynard T</AU>
<TI>Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?</TI>
<SO>Journal of Hepatology</SO>
<YR>2011</YR>
<VL>55</VL>
<NO>2</NO>
<PG>483-5</PG>
<IDENTIFIERS MODIFIED="2012-01-16 17:35:01 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vilstrup-2006" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Vilstrup 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vilstrup H, Markiewicz M, Biesma D, Brozovic VV, Laminoga N, Malik M, et al</AU>
<TI>Recombinant activated factor VII in an unselected series of cases with upper gastrointestinal bleeding</TI>
<SO>Thrombosis Research</SO>
<YR>2006</YR>
<VL>118</VL>
<PG>595-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Afessa-2000" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Afessa 2000" TYPE="JOURNAL_ARTICLE">
<AU>Afessa B, Kubilis PS</AU>
<TI>Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<PG>484-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aitken-2004" MODIFIED="2012-01-16 17:37:17 +0100" MODIFIED_BY="[Empty name]" NAME="Aitken 2004" TYPE="JOURNAL_ARTICLE">
<AU>Aitken MG</AU>
<TI>Recombinant factor VIIa</TI>
<SO>Emergency Medicine Australasia</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>5-6</NO>
<PG>446-55</PG>
<IDENTIFIERS MODIFIED="2012-01-16 17:37:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-16 17:35:50 +0100" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15537408"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Allen-2002" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd</AU>
<TI>Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2002</YR>
<VL>49 Suppl</VL>
<PG>7-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1995" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>485</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amitrano-2002" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Amitrano 2002" TYPE="JOURNAL_ARTICLE">
<AU>Amitrano L, Guardascione MA, Brancaccio V, Balzano A</AU>
<TI>Coagulation disorders in liver disease</TI>
<SO>Seminars in Liver Disease</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>83-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bernstein-1997" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bernstein 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, et al</AU>
<TI>Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>113</VL>
<NO>6</NO>
<PG>1930-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boutron-2010" MODIFIED="2010-09-16 23:05:23 +0200" MODIFIED_BY="[Empty name]" NAME="Boutron 2010" TYPE="JOURNAL_ARTICLE">
<AU>Boutron I, Dutton S, Ravaud P, Altman DG</AU>
<TI>Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>26</VL>
<PG>2058-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2003" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2003" TYPE="JOURNAL_ARTICLE">
<AU>Brown JB, Emerick KM, Brown DL, Whitington PF, Alonso EM</AU>
<TI>Recombinant factor VIIa improves coagulopathy caused by liver failure</TI>
<SO>Journal of Pediatric Gastroenterology and Nutrition</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>268-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czernichow-2000" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Czernichow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Czernichow P, Hochain P, Nousbaum JB, Raymond JM, Rudelli A, Dupas JL, et al</AU>
<TI>Epidemiology and course of acute upper gastro-intestinal haemorrhage in four French geographical areas</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dallal-2001" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Dallal 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dallal HJ, Palmer KR</AU>
<TI>ABC of the upper gastrointestinal tract: upper gastrointestinal haemorrhage</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1115-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-del-Olmo-2000" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="del Olmo 2000" TYPE="JOURNAL_ARTICLE">
<AU>del Olmo JA, Pena A, Serra MA, Wassel AH, Benages A, Rodrigo JM</AU>
<TI>Predictors of morbidity and mortality after the first episode of upper gastrointestinal bleeding in liver cirrhosis</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erhardtsen-2000" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Erhardtsen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Erhardtsen E</AU>
<TI>Pharmacokinetics of recombinant activated factor VII (rFVIIa)</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>4</NO>
<PG>385-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erhardtsen-2002" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Erhardtsen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Erhardtsen E</AU>
<TI>Ongoing NovoSeven trials</TI>
<SO>Intensive Care Medicine</SO>
<YR>2002</YR>
<VL>28 Suppl</VL>
<PG>248-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fermi-Paradox" MODIFIED="2011-12-20 13:38:36 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Fermi Paradox" TYPE="OTHER">
<TI>Fermi Paradox</TI>
<SO>www.crystalinks.com/fermiparadox.html</SO>
<YR>(accessed 20 December 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Franchini-2010" MODIFIED="2010-09-17 00:12:29 +0200" MODIFIED_BY="[Empty name]" NAME="Franchini 2010" TYPE="JOURNAL_ARTICLE">
<AU>Franchini M, Lippi G</AU>
<TI>Recombinant activated factor VII: mechanisms of action and current indications</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>2010</YR>
<VL>36</VL>
<PG>485-92</PG>
<IDENTIFIERS MODIFIED="2010-09-17 00:12:29 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Freiman-1978" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Freiman 1978" TYPE="JOURNAL_ARTICLE">
<AU>Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR</AU>
<TI>The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>299</VL>
<PG>690-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2011" MODIFIED="2011-12-20 13:18:45 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Gluud 2011" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2011, Issue 12. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2002" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Green 2002" TYPE="JOURNAL_ARTICLE">
<AU>Green SB</AU>
<TI>Design of randomized trials</TI>
<SO>Epidemiologic Reviews</SO>
<YR>2002</YR>
<VL>24</VL>
<PG>4-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Green-2003" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Green 2003" TYPE="JOURNAL_ARTICLE">
<AU>Green BT, Rockey DC</AU>
<TI>Acute gastrointestinal bleeding</TI>
<SO>Seminars in Gastrointestinal Disease</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>2</NO>
<PG>44-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, GRADE Working Group</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebert-2002" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Hebert 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hebert RS, Wright SM, Dittus RS, Elasy TA</AU>
<TI>Prominent medical journals often provide insufficient information to assess the validity of studies with negative results</TI>
<SO>Journal of Negative Results in BioMedicine</SO>
<YR>2002</YR>
<VL>1</VL>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2011-12-20 13:21:09 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2011-11-26 18:22:54 +0100" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>Meta-research: The art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirby-2002" MODIFIED="2011-12-20 13:21:29 +0100" MODIFIED_BY="[Empty name]" NAME="Kirby 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kirby A, Gebski V, Keech AC</AU>
<TI>Determining the sample size in a clinical trial</TI>
<SO>The Medical Journal of Australia</SO>
<YR>2002</YR>
<VL>177</VL>
<PG>256-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2011-12-20 12:37:07 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NERI-2003" MODIFIED="2011-12-20 13:25:18 +0100" MODIFIED_BY="[Empty name]" NAME="NERI 2003" TYPE="OTHER">
<AU>New England Research Institutes (NERI)</AU>
<TI>The positives of negative results</TI>
<SO>http://www.neriscience.com/Portals/0/Uploads/Documents/fall2003.pdf</SO>
<YR>(accessed 20 December 2011)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Connell--2006" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="O'Connell  2006" TYPE="JOURNAL_ARTICLE">
<AU>O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM</AU>
<TI>Thromboembolic adverse events after use of recombinant human coagulation factor VIIa</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Hara-2006" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="O'Hara 2006" TYPE="JOURNAL_ARTICLE">
<AU>O'Hara B, Fowler MS, Johnson CA</AU>
<TI>Why negatives should be viewed as positives</TI>
<SO>Nature</SO>
<YR>2006</YR>
<VL>439</VL>
<PG>782</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paramo-1993" MODIFIED="2010-09-16 23:05:58 +0200" MODIFIED_BY="[Empty name]" NAME="Paramo 1993" TYPE="JOURNAL_ARTICLE">
<AU>Paramo JA, Rocha E</AU>
<TI>Hemostasis in advanced liver disease</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1993</YR>
<VL>19</VL>
<PG>184-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pavese-2005" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Pavese 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pavese P, Bonadona A, Beaubien J, Labrecque P, Pernod G, Letoublon C, et al</AU>
<TI>FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2005</YR>
<VL>52</VL>
<PG>26-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Protell-1981" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Protell 1981" TYPE="JOURNAL_ARTICLE">
<AU>Protell RL, Silverstein FE, Gilbert DA, Feld AD</AU>
<TI>Severe upper gastrointestinal bleeding. Part I: Causes, pathogenesis and methods of diagnosis</TI>
<SO>Clinics in Gastroenterology</SO>
<YR>1981</YR>
<VL>10</VL>
<PG>17-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-12-20 13:25:46 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre: The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2011-12-20 12:40:23 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silva-de-Lima-2004" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Silva de Lima 2004" TYPE="JOURNAL_ARTICLE">
<AU>Silva de Lima M, Garcia de Oliveira Soares B</AU>
<TI>The value of publishing negative results from a randomized controlled trial: the Rosenheck's study</TI>
<TO>O valor de publicar-se resultados negativos de ensaios clínicos randomizados: o estudo de Rosenheck</TO>
<SO>Revista Brasileira de Psiquiatria</SO>
<YR>2004</YR>
<VL>26</VL>
<PG>135</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tonda-2003" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Tonda 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tonda R, Galan AM, Pino M, Cirera I, Bosch J, Hernandez MR, et al</AU>
<TI>Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>39</VL>
<PG>954-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tripodi-2005" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Tripodi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al</AU>
<TI>Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests</TI>
<SO>Hepatology</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>553-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2011-12-20 13:26:45 +0100" MODIFIED_BY="[Empty name]" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>Trial Sequential Analysis</TI>
<YR>2011</YR>
<PB>Copenhagen Trial Unit, Centre for Clinical Intervention Research</PB>
<CY>Copenhagen, Denmark</CY>
<MD>http: www.ctu.dk/tsa</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Thiel-2005" MODIFIED="2008-11-09 14:02:08 +0100" MODIFIED_BY="[Empty name]" NAME="Van Thiel 2005" TYPE="JOURNAL_ARTICLE">
<AU>Van Thiel DH, Farr DE, Mindikoglu AL, Todo A, George MM</AU>
<TI>Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>882-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2011-12-20 13:32:48 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-03-17 17:37:49 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2007" MODIFIED="2011-03-17 17:37:49 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2007" TYPE="COCHRANE_REVIEW">
<AU>Marti-Carvajal AJ, Salanti G, Marti-Carvajal PI</AU>
<TI>Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-03-17 17:37:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-03-17 17:37:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004887.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-01-16 15:16:56 +0100" MODIFIED_BY="Arturo Marti"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosch-2004">
<CHAR_METHODS MODIFIED="2011-01-04 19:02:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial, parallel design (two arms).<BR/>Multicentre study. International: Europe (26 hospitals).<BR/>Follow-up period: 42 days after first trial product administration.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>N = 245 randomised.<BR/>N = 242 dosed.<BR/>rHuFVIIa group: 121.<BR/>Placebo group: 121.</P>
<P>Loss after randomisation: 1.22% (3/245):<BR/>Transjugular intrahepatic porto-systemic shunt (TIPS) in place (n =1), withdrawal of consent (n = 1), previous cerebrovascular accident (n = 1).</P>
<P>Analysed for primary outcome:</P>
<P>Among randomised participants: 96.7% (237/245).<BR/>Among the dosed-participants: 97.9% (237/242).<BR/>rHuFVIIa group: 97.5% (118/121).<BR/>Placebo group: 98.3% (119/121).<BR/>
</P>
<P>Sex (male):<BR/>- rHuFVIIa group: 74%.<BR/>- Placebo group: 74%.<BR/>Age (years):<BR/>- rHuFVIIa group: 52.6 ± 11.9.<BR/>- Placebo group: 54.2 ± 10.6.<BR/>
</P>
<P>Inclusion criteria:<BR/>(1) Signs of active acute UGIB suspected to be of variceal origin (haematemesis or melena within 24 hours of inclusion) requiring hospitalisation and volume replacement therapy.<BR/>(2) Cirrhosis, either confirmed histologically or with obvious clinical or endoscopic signs of cirrhosis and portal hypertension.<BR/>(3) Age 18 to 74 years.<BR/>(4) Scheduled to undergo endoscopy within 12 hours of hospital admission (or within 12 hours index bleed if already hospitalised).<BR/>(5) Initiation of trial product administration before first endoscopy and within 6 hours of admission (or within 6 hours of index bleed if already hospitalised).</P>
<P>
<BR/>Exclusion criteria:<BR/>(1) Known hypercoagulability.<BR/>(2) Acquired FVIII deficiency, or hereditary bleeding disorder.<BR/>(3) History of pulmonary embolism or deep vein thrombosis, history of either portal thrombosis, stable/unstable angina pectoris, myocardial infarction, intermittent claudication, or transient Ischaemic attack/ischaemic stroke.<BR/>(4) Signs of cardiac ischaemia.<BR/>(5) Concomitant disease with a life expectancy of less than six months.<BR/>(6) Tense ascites and obvious jaundice.<BR/>(7) Grade IV encephalopathy.<BR/>(8) Sclerotherapy or band ligation within two weeks.<BR/>(9) Previous transjugular intrahepatic portosystemic shunt or orthotopic liver transplantation.<BR/>(10) Known gastrointestinal/respiratory system cancer/hepatocellular carcinoma.<BR/>(11) Planned use of any haemostatic drug other than rHuFVIIa in the management of the bleeding episode.<BR/>(12) Known advanced cirrhosis reflected in a known Child-Pugh score &#8805; 12 points at trial entry.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Experimental group:</LI>
</UL>
<P>Recombinant FVIIa (rHuFVIIa) 8 doses at 100 µg/kg. First dose was administered as a slow intravenous injection before first endoscopy and within 6 hours of admission (or within 6 hours of index bleeding if the patient was already hospitalised). Further doses were administered at 2, 4, 6, 12, 18, 24, and 30 hours after the first dose.</P>
<UL>
<LI>Control group:</LI>
</UL>
<P>Placebo: 8 doses at 100 µg/kg.</P>
<P>*NovoSeven placebo: freeze dried powder for injection - non-active. Calcium chloride dihydrate: 1.47 mg per mL rHuFVIIa, sodium chloride: 2.92 mg per mL rHuFVIIa, glycylglycine: 1.32 mg per mL rHuFVIIa, mannitol: 30 mg per mL rHuFVIIa, polysorbate 80: 0.07 mg per mL rHuFVIIa.</P>
<P>
<BR/>Co-interventions:</P>
<P>(1) Standard pharmacologic and endoscopic treatment.<BR/>(2) Blood transfusion were given to keep haematocrit level between 25% to 30%.<BR/>(3) Vasoactive treatment with either terlipressin, somatostatin, or octreotide was used.</P>
<P>Treatment scheme: 2, 4, 6, 12, 18, 24, and 30 hours after first dose.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>(A) Primary outcome:<BR/>(1) Control of acute bleeding.<BR/>(2) Prevention of rebleeding.<BR/>(3) Mortality over the 5-day trial period.<BR/>
</P>
<P>
<B>Composite outcome consisting of the following three outcomes</B>:<BR/>(1) <I>Failure to control bleeding within 24 hours</I> after first dose of trial product. <I>Failure within 0 to 6 hours</I> was defined as transfusion of &#8805; 4 units of blood (whole blood or red blood cells) together with an inability to achieve an increase in systolic blood pressure by 20 mm Hg or to 70 mm Hg or more. <I>Failure within 6 to 24 hours</I> was defined by the presence of a new haematemesis together with (a) a decrease in systolic blood pressure 20 mm Hg and/or (b) a transfusion of &#8805; 2 units of blood (whole blood or red blood cells) in addition to the earlier transfusions (given from 0 to 6 hours) to increase haemoglobin level to 9g/dL. <I>Failure to control acute UGIB</I> if balloon tamponade was used within 24 hours after first trial product administration.<BR/>(2) <I>Failure to prevent rebleeding between 24 hours and 5 days</I> defined by the occurrence of new haematemesis and/or new melena together with transfusion of &#8805; 2 units of blood (whole blood or red blood cells) in any 24-hour period in which 1 or more of the 3 after haemodynamic criteria were fulfilled: (a) systolic blood pressure less than 100 mm Hg, (b) postural change more than 20 mm Hg, or (c) pulse rate more than 100 beats/min. In addition to these Baveno II criteria, it was regarded as a failure to prevent rebleeding if balloon tamponade was used within 5 days after first trial product administration.<BR/>(3) Death within 0 to 5 days after first trial product administration.<BR/>Failure on the primary composite outcome was defined as failure on at least one of the three outcomes constituting the composite outcome.</P>
<P>(B) Secondary outcomes:<BR/>(1) Control of acute bleeding and prevention of rebleeding.<BR/>(2) Active bleeding at first endoscopy.<BR/>(3) 5-day and 6-week mortality.<BR/>(4) Transfusion requirements.<BR/>(5) Number of emergency and elective procedures performed.<BR/>(6) Length of stay in the intensive care unit or hospital.<BR/>(7) Frequency of adverse events including thromboembolic events, changes in coagulation-related parameters, haematology and blood chemistry parameters.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-12-19 14:08:03 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size was planned to detect a decrease in failure rate on the primary outcome from 30% in the placebo group to 15% in the rHuFVIIa group. Statistical power: 80%.<BR/>Significance level: 5%.</P>
<P>The authors received additional information on the trial from Søren Fabricius (30-06-2006) and J Bosch (30-06-2006).</P>
<P>ID: not reported.</P>
<P>Trial period: April 2001 to April 2002.<BR/>Supported: Novo Nordisk A/S, Copenhagen, Denmark.<BR/>Role of sponsor: not described.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosch-2008">
<CHAR_METHODS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial, parallel design (three arms).<BR/>International, multicentre study: Europe and Asia (31 hospitals in 12 countries).<BR/>
<BR/>Day trial period: five days.<BR/>Final follow-up period (days): 42 after first trial product administration (range: 42 to 46).<BR/>
<BR/>The primary analysis: comparison of the proportion of treatment failures in the 600 &#956;g/kg group and placebo. "Whenever a significant difference was found, the 300 &#956;g/kg group and placebo were subsequently compared".<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>N = 265.<BR/>600 &#956;g/kg rHuFVIIa group: 88.<BR/>300 &#956;g/kg rHuFVIIa group: 88.<BR/>Placebo group: 89.</P>
<P>Completed trial: 98.1% (260/265).<BR/>600 &#956;g/kg rHuFVIIa group: 99.0% (87/88).<BR/>300 &#956;g/kg rHuFVIIa group: 95.4% (84/88).<BR/>Placebo group: 100% (89/89).</P>
<P>Loss after intervention (600 &#956;g/kg rHuFVIIa): 1% (1/88): one withdrawal due to uncontrolled bleeding).<BR/>Loss after intervention (300 &#956;g/kg rHuFVIIa): 4.6% (4/88): violation exclusion criteria (n = 2), family withdrew consent (n =1), adverse event (n=1).<BR/>Placebo group: 0.<BR/>
<BR/>Analysed for primary outcome: 97% (256/265).<BR/>600 &#956;g/kg rHuFVIIa group: 96.6% (85/88): excluded due to no active bleeding (n = 3).<BR/>300 &#956;g/kg rHuFVIIa group: 96.6% (85/88): excluded due to no active bleeding (n = 2), Child-Pugh &lt; 9 (n = 1).<BR/>Placebo group: 96.6% (86/89): excluded due to no active bleeding (n = 2), other (n = 1).<BR/>
</P>
<P>Sex (male):<BR/>- 600 &#956;g/kg rHuFVIIa group: 66%.<BR/>- 300 &#956;g/kg rHuFVIIa group: 75%.<BR/>- Placebo group: 78%.<BR/>Age (years):<BR/>- 600 &#956;g/kg rHuFVIIa group: 55.0±11.3.<BR/>- 300 &#956;g/kg rHuFVIIa group: 54.7±11.7.<BR/>- Placebo group: 53.9 ± 10.2.<BR/>
<BR/>Inclusion criteria:<BR/>(1) Age: 18 to 79 years of age.<BR/>(2) Acute upper gastrointestinal bleeding (UGIB) and advanced cirrhosis.<BR/>(3) Child-Pugh score more than 8.<BR/>(4) Treatment with vasoactive therapy at least 0.5 hours before endoscopy showing active oesophageal or gastroesophageal variceal bleeding (oozing/spurting), endoscopy performed within 6 hours (±6 hours) of admittance to emergency room.<BR/>(5) First trial product dose within 1 hour of endoscopy with therapy (either ligation or sclerotherapy).</P>
<P>
<BR/>Exclusion criteria:<BR/>(1) Unfit for resuscitation.<BR/>(2) Band ligation within two weeks or sclerotherapy within one week.<BR/>(3) Clinically documented symptoms of unstable angina, peripheral vascular disease, and/or known previous<BR/>myocardial/ pulmonary infarction or stroke; electrocardiogram (12-lead) verified signs of cardiac ischaemia.<BR/>(4) History of pulmonary embolism.<BR/>(5) Portal/deep vein thrombosis within 6 months or history of recurrent deep vein thrombosis.<BR/>(6) Previous diagnosis of advanced hepatocellular carcinoma.<BR/>(7) Pregnancy.<BR/>(8) Previous dosing with trial drug in this trial.<BR/>(9) Receipt of any investigational drug within six weeks.<BR/>(10) Known thrombogenic disorder, acquired FVIII deficiency, acquired haemophilia, or hereditary bleeding disorder.<BR/>(11) Known or suspected allergy/hypersensitivity to rHuFVIIa.<BR/>(12) Planned use of antifibrinolytic drugs.<BR/>(13) Planned haemofiltration or dialysis within five days of screening.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Intervention (rHuFVIIa):</LI>
</UL>
<P>- 600 &#956;g/kg rHuFVIIa group (200 plus 4 x 100 &#956;g/kg);</P>
<P>- 300 &#956;g/kg rHuFVIIa group (200, 100 &#956;g/kg plus 3 x placebo)</P>
<UL>
<LI>Control group:</LI>
</UL>
<P>- Placebo group: not described.</P>
<P>Treatment scheme:<BR/>First dose: intravenously (over 2 minutes) at 0 hour as soon as possible after confirmation of active bleeding and &#8804; 1 hour after therapeutic endoscopy.<BR/>Subsequent doses: 2, 8, 14, and 20 hours (± 15 minutes) after the first dose.</P>
<P>
<BR/>Co-interventions:<BR/>(1) Standard vasoactive treatment (somatostatin and analogues, or terlipressin, initiated as soon as variceal bleeding was suspected and at least 0.5 hour prior to endoscopy).<BR/>(2) Prophylactic antibiotic therapy (initiated as soon as possible and no later than 12 hours after emergency room admission).<BR/>(3) Endoscopic treatment.<BR/>(4) Transfusions: to maintain an haematocrit (25% to 30%) and platelets (30,000 &#956;L).<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Primary:<BR/>Treatment failure (modified Baveno II-IV criteria)* "failure to control acute bleeding within 24 hours, or failure to prevent clinically significant rebleeding, or death within 5 days of first trial product dosing".<BR/>
<BR/>Secondary:<BR/>(1) 5-day and 42-day mortality.<BR/>(2) Failure to control 5-day bleeding.<BR/>(3) Failure to control acute bleeding within 24 hours.<BR/>(4) Failure to prevent clinically significant rebleedings and all rebleedings at day 5.<BR/>(5) Number of emergency procedures within five days.<BR/>(6) Transfusion requirements at 24 hours and day 5.<BR/>
<BR/>Secondary safety endpoints:<BR/>(1) Frequency of adverse events (recorded up to day 42).<BR/>(2) Changes in coagulation-related parameters (measured using standard methods, between baseline and day 5).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Sample size calculation criteria (reduction from 40% in placebo; reduction to 20% in each rHuFVIIa group, power: 87%.<BR/>P = 5%): 258 participants.<BR/>* Failure to control 24-hour bleeding: new hematemesis, a reduction in systolic blood pressure of &#8805; 20 mmHg, and/or transfusion of &#8805; 2 U blood (whole or packed red blood cells - pRBCs - over and above the amount required to increase hematocrit to 25%-30%.<BR/>* Clinically significant rebleeding: both new haematemesis/melena and transfusion of 2 U blood (whole or pRBCs) in any 24-hour period.<BR/>* A 24-hour bleeding-free period: 24 hours without haematemesis/melena, with stable haemoglobin (without transfusions) and stable arterial blood pressure.</P>
<P>ID: NCT00154492</P>
<P>Trial period: April 2004 to August 2006.</P>
<P>Sponsored: Novo Nordisk A/S, 2880 Bagsvaerd, Denmark.<BR/>Role of sponsor: design and analysis.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>* This information was supplied by Søren Fabricius, International Trial Manager, Novo Nordisk A/S, Copenhagen, Denmark. Date: February 6, 2005.<BR/>UGIB = upper gastrointestinal bleeding.</P>
<P>&#8805; = more or equal to.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-01-17 14:06:46 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-01-17 14:06:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arellano_x002d_Rodrigo-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-17 14:06:22 +0100" MODIFIED_BY="[Empty name]">
<P>Letter of the editor on safety.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-07 12:17:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bosch-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-07 12:17:49 +0200" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-16 16:03:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ejlersen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-16 16:03:30 +0100" MODIFIED_BY="[Empty name]">
<P>Case report. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-07 12:17:52 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flower-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-07 12:17:52 +0200" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-07 12:17:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franchini-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-07 12:17:54 +0200" MODIFIED_BY="[Empty name]">
<P>Narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-17 14:06:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-17 14:06:31 +0100" MODIFIED_BY="[Empty name]">
<P>Review on safety of recombinant activated Factor VII in randomised controlled trials.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-07 12:17:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mart_x00ed__x002d_Carvajal-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-07 12:17:56 +0200" MODIFIED_BY="[Empty name]">
<P>Systematic review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Plessier--2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romero_x002d_Castro-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case reports.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-17 14:06:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thabut-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-17 14:06:46 +0100" MODIFIED_BY="[Empty name]">
<P>Comment on a paper related to human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-07-07 12:18:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vilstrup-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-07-07 12:18:02 +0200" MODIFIED_BY="[Empty name]">
<P>Report of cases.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-03-22 18:00:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-24 08:56:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>Computer-generated and stratified by trial centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 18:00:42 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>Quote "ensuring immediate randomisation through a central interactive voice-response system and rapid administration of trial product to patients diagnosed with active bleeding". "Computer-generated and stratified by trial centre" (page 1605).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-05-06 18:49:56 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 19:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>Central interactive voice-response system to administer trial drug. Treatment allocation was kept in sealed envelopes. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-06 18:49:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>Central interactive voice-response system to administer trial drug (page 1605).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-05-09 17:46:13 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2011-05-09 17:41:06 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-09 17:32:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>Quote "To maintain double blinding, treatment allocation was kept in sealed envelopes during the trial, and an equal volume per body weight of trial product was administered to all patients irrespective of treatment allocation." (page 1124).<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-05-09 17:41:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>Quote "Trial product boxes were packed in a blinded fashion and box number denoted randomisation number" (page 1605).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>Insufficient information to consider 'Yes' or 'No'.<BR/>Comments: 'serious adverse event' was not defined.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-05-09 17:43:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>Quote:"... a blinded clinical evaluation committee continuously reviewed all case report forms to check patient eligibility and protocol compliance, and to validate the patient outcome classifications" (page 1606).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-07 18:33:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>Quote No.1: "A minority of patients could not be assessed on failure end points, primarily because they withdrew consent or were lost to follow-up evaluation on or before day 5". (Page 1126).</P>
<P>Quote No.2: "Three of these patients, however, were withdrawn before dosing..." (Page 1125).<BR/>
<BR/>
</P>
<P>Available for analysis:<BR/>rHuFVIIa group: 97.5% (118/121).<BR/>Placebo group: 98.3% (119/121).</P>
<P>Very few individuals (with overall dropout rate lower than the event rate) were lost to follow-up and the numbers do not differ between arms. The reasons for dropout are unlikely to introduce bias.<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>Quote No.1: "Nine subjects (three in each group) were excluded from ITT analysis (due to non-active variceal bleeding, Child-Pugh score &lt;9 or non acceptance of protocol amendment by the health authority), but were included in the safety analysis". (page 1608).</P>
<P>Analyzed for primary outcome: 97% (256/265).<BR/>600 &#956;g/kg rHuFVIIa group: 96.6% (85/88): excluded due to no active bleeding (n = 3).<BR/>300 &#956;g/kg rHuFVIIa group: 96.6% (85/88): excluded due to no active bleeding (n = 2), Child-Pugh less than 9 (n = 1).<BR/>Placebo group: 96.6% (86/89): excluded due to no active bleeding (n = 2), other (n = 1).</P>
<P>Comment: Missing data (with overall dropout rate lower than the event rate) are unlikely to bias the result as they are few and balanced between arms.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-03-22 17:57:11 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-22 17:57:11 +0100" MODIFIED_BY="Dimitrinka Nikolova" RESULT="YES" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>The study protocol is not available, but it is clear that the published reports include all expected outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-02 19:37:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>Comments:<BR/>This RCT include all expected outcomes, including those that were pre-specified in the protocol published inhttp://clinicaltrials.gov/ct2/show/NCT00154492?term=NCT+00154492&amp;rank=1.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-01-04 19:03:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-04 19:02:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bosch-2004">
<DESCRIPTION>
<P>Novo Nordisk supported the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-01-04 19:03:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bosch-2008">
<DESCRIPTION>
<P>
<B> </B>Novo Nordisk is the sponsor of this trial (potential conflict of interest mentioned). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-02-14 14:09:15 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-02-14 14:09:15 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="Grade Profiler">Recombinant human factor VII activated compared to placebo for upper gastrointestinal bleeding and liver diseases.</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>Recombinant human factor VII activated compared to placebo for upper gastrointestinal bleeding in patients with liver diseases</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with upper gastrointestinal bleeding and liver diseases.<BR/>
<B>Settings:</B> hospitalised.<BR/>
<B>Intervention:</B> recombinant human factor VII activated.<BR/>
<B>Comparison: </B>placebo.</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Recombinant human factor VII activated</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality within 5 days</B>
<BR/>Follow-up: 5 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>73 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>69 per 1000</B>
<BR/>(26 to 183)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
<BR/>(0.36 to 2.5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>493<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mortality within 42 days</B>
<BR/>Follow-up: 42 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>178 per 1000</B>
<BR/>(97 to 329)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.01 </B>
<BR/>(0.55 to 1.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>491<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events (overall incidence)</B>
<BR/>Follow-up: 42 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>781 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>734 per 1000</B>
<BR/>(656 to 812)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.94 </B>
<BR/>(0.84 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>507<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Serious adverse events by total adverse events</B>
<BR/>Follow-up: 42 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>278 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>250 per 1000</B>
<BR/>(203 to 303)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.90 </B>
<BR/>(0.73 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1043<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Thromboembolic events by patients</B>
<BR/>Follow-up: 42 days</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
<BR/>(27 to 107)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.80 </B>
<BR/>(0.4 to 1.6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>507<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>8,9</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (eg, the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Statistical heterogeneity (I<SUP>2</SUP>) = 49%.<BR/>
<SUP>2</SUP> 36 events and 493 participants.<BR/>
<SUP>3</SUP> Statistical heterogeneity (I<SUP>2</SUP>) = 55%.<BR/>
<SUP>4</SUP> 91 events and 491 participants.<BR/>
<SUP>5</SUP> Statistical heterogeneity (I<SUP>2</SUP>) = 1%.<BR/>
<SUP>6</SUP> Statistical heterogeneity (I<SUP>2</SUP>) = 0%.<BR/>
<SUP>7</SUP> 287 serious adverse events and 1043 total adverse events.<BR/>
<SUP>8</SUP> Statistical heterogeneity (I<SUP>2</SUP>) = 0%.<BR/>
<SUP>9</SUP> 30 events and 507 patients.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-09-16 21:13:30 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-12-19 14:26:53 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-12-19 14:23:08 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Mortality (available cases analysis)</NAME>
<DICH_OUTCOME CHI2="1.965078207907322" CI_END="1.6408088692512928" CI_START="0.4762637166101034" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8840009786852285" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="49.11144014644925" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.21505799490814298" LOG_CI_START="-0.3221525032590126" LOG_EFFECT_SIZE="-0.05354725417543484" METHOD="MH" MODIFIED="2011-12-19 14:23:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16097156098136522" P_Q="1.0" P_Z="0.6960007835389816" Q="0.0" RANDOM="NO" SCALE="391.58" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="288" TOTAL_2="205" WEIGHT="100.0" Z="0.3907246415061993">
<NAME>Deaths within 5 days</NAME>
<GROUP_LABEL_1>rHFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHuFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.869964464081564" CI_START="0.5306040168898974" EFFECT_SIZE="1.7648305084745763" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7686354720994031" LOG_CI_START="-0.2752294665540034" LOG_EFFECT_SIZE="0.24670300277269985" MODIFIED="2010-10-17 11:06:25 +0200" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.6131714321797931" STUDY_ID="STD-Bosch-2004" TOTAL_1="118" TOTAL_2="119" VAR="0.3759792052414186" WEIGHT="21.423277815404365"/>
<DICH_DATA CI_END="1.3574373813378866" CI_START="0.3053865854175253" EFFECT_SIZE="0.6438502673796791" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.1327198046942824" LOG_CI_START="-0.5151500439236688" LOG_EFFECT_SIZE="-0.19121511961469326" MODIFIED="2010-10-17 11:06:56 +0200" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.3805619560856572" STUDY_ID="STD-Bosch-2008" TOTAL_1="170" TOTAL_2="86" VAR="0.14482740241974168" WEIGHT="78.57672218459564"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.22840050141234" CI_END="1.8722043718856267" CI_START="0.5486039251637591" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.013458764393108" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="36" I2="55.12476328352066" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.27235325505249774" LOG_CI_START="-0.26074108942040153" LOG_EFFECT_SIZE="0.005806082816048113" METHOD="MH" MODIFIED="2011-12-19 14:23:08 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1354941448263388" P_Q="1.0" P_Z="0.9659462154507304" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11332965407872361" TOTALS="YES" TOTAL_1="286" TOTAL_2="205" WEIGHT="100.0" Z="0.04269305547393498">
<NAME>Deaths within 42 days</NAME>
<GROUP_LABEL_1>rHFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHuFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.077286546834224" CI_START="0.7235434246204138" EFFECT_SIZE="1.4921630094043887" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" LOG_CI_END="0.48816793820870064" LOG_CI_START="-0.1405353988820766" LOG_EFFECT_SIZE="0.173816269663312" MODIFIED="2011-01-04 17:54:31 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.369303452338833" STUDY_ID="STD-Bosch-2004" TOTAL_1="116" TOTAL_2="119" VAR="0.1363850399093807" WEIGHT="39.26804283303922"/>
<DICH_DATA CI_END="1.2131566816033053" CI_START="0.5133710353942191" EFFECT_SIZE="0.7891764705882353" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="25" LOG_CI_END="0.08391689448685875" LOG_CI_START="-0.2895686380473479" LOG_EFFECT_SIZE="-0.10282587178024462" MODIFIED="2010-10-17 11:09:31 +0200" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.21938725059379588" STUDY_ID="STD-Bosch-2008" TOTAL_1="170" TOTAL_2="86" VAR="0.048130765723104985" WEIGHT="60.73195716696079"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-12-19 14:26:17 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Worst-case scenario mortality</NAME>
<DICH_OUTCOME CHI2="2.2080367878285663" CI_END="3.5819884372796076" CI_START="0.5214786698480457" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3667225635379148" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="15" I2="54.7108994962252" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.554124179605205" LOG_CI_START="-0.28276345091289457" LOG_EFFECT_SIZE="0.13568036434615524" METHOD="MH" MODIFIED="2011-12-19 14:23:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13729337866033764" P_Q="1.0" P_Z="0.5250905552769558" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2763156993229871" TOTALS="YES" TOTAL_1="297" TOTAL_2="210" WEIGHT="100.0" Z="0.6355181217414001">
<NAME>Deaths within 5 days</NAME>
<GROUP_LABEL_1>rHFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.753235503053729" CI_START="0.8061150725446611" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.8894829757821423" LOG_CI_START="-0.0936029584380671" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2011-01-04 18:01:15 +0100" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.577469544114809" STUDY_ID="STD-Bosch-2004" TOTAL_1="121" TOTAL_2="121" VAR="0.3334710743801653" WEIGHT="39.63067793118124"/>
<DICH_DATA CI_END="1.8333405704146197" CI_START="0.46109047359132976" EFFECT_SIZE="0.9194214876033058" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.2632431491481801" LOG_CI_START="-0.3362138504751419" LOG_EFFECT_SIZE="-0.03648535066348089" MODIFIED="2011-01-04 18:26:50 +0100" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.35212400893874446" STUDY_ID="STD-Bosch-2008" TOTAL_1="176" TOTAL_2="89" VAR="0.12399131767109298" WEIGHT="60.36932206881877"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3296884933148796" CI_END="2.5850902692006876" CI_START="0.6070349985571123" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2526932057907254" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="36" I2="69.96716053145117" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.41247571289660007" LOG_CI_START="-0.21678626898726003" LOG_EFFECT_SIZE="0.09784472195467005" METHOD="MH" MODIFIED="2011-12-19 14:26:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06803983366473565" P_Q="1.0" P_Z="0.5421835101097635" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.19488270800023297" TOTALS="YES" TOTAL_1="297" TOTAL_2="210" WEIGHT="100.0" Z="0.6095144363699484">
<NAME>Deaths within 42 days</NAME>
<GROUP_LABEL_1>rHFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7856247981772686" CI_START="0.9627547085301209" EFFECT_SIZE="1.9090909090909092" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.5781375678538683" LOG_CI_START="-0.016484348702479876" LOG_EFFECT_SIZE="0.2808266095756942" MODIFIED="2011-01-04 18:02:03 +0100" MODIFIED_BY="[Empty name]" ORDER="23" O_E="0.0" SE="0.34928385721115685" STUDY_ID="STD-Bosch-2004" TOTAL_1="121" TOTAL_2="121" VAR="0.12199921290830382" WEIGHT="43.11622499186612"/>
<DICH_DATA CI_END="1.381423200931336" CI_START="0.599753708680987" EFFECT_SIZE="0.9102272727272728" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="25" LOG_CI_END="0.14032674568478032" LOG_CI_START="-0.2220270578166422" LOG_EFFECT_SIZE="-0.04085015606593095" MODIFIED="2011-01-04 18:27:06 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.21284841785699105" STUDY_ID="STD-Bosch-2008" TOTAL_1="176" TOTAL_2="89" VAR="0.04530444898422426" WEIGHT="56.88377500813388"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2011-12-19 14:26:34 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Best-case scenario mortality</NAME>
<DICH_OUTCOME CHI2="1.6756178500505994" CI_END="1.5436564255442309" CI_START="0.31323502224729327" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6953612405056269" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" I2="40.320521175529215" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.1885506450319187" LOG_CI_START="-0.5041296862104802" LOG_EFFECT_SIZE="-0.15778952058928075" METHOD="MH" MODIFIED="2011-12-19 14:24:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.19550783342745037" P_Q="1.0" P_Z="0.3718880929913382" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.14151972983892153" TOTALS="YES" TOTAL_1="297" TOTAL_2="210" WEIGHT="100.0" Z="0.8929422810032337">
<NAME>Deaths within 5 days</NAME>
<GROUP_LABEL_1>rHFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.370495010186815" CI_START="0.4038312197458704" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5276936885286787" LOG_CI_START="-0.39380010926745224" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2011-01-04 18:05:53 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.5412900182933128" STUDY_ID="STD-Bosch-2004" TOTAL_1="121" TOTAL_2="121" VAR="0.2929948839039749" WEIGHT="38.10101353204056"/>
<DICH_DATA CI_END="1.0137974839867319" CI_START="0.25223390793403877" EFFECT_SIZE="0.5056818181818182" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.0059512090692387005" LOG_CI_START="-0.5981965314077127" LOG_EFFECT_SIZE="-0.29612266116923697" MODIFIED="2011-01-04 18:29:53 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.3548793733357081" STUDY_ID="STD-Bosch-2008" TOTAL_1="176" TOTAL_2="89" VAR="0.1259393696191449" WEIGHT="61.89898646795944"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.378736754647334" CI_END="1.6814411134763096" CI_START="0.48992346494526084" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9076218686301754" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="40" I2="57.960879948304424" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.22568166228989736" LOG_CI_START="-0.30987175945732787" LOG_EFFECT_SIZE="-0.042095048583715225" METHOD="MH" MODIFIED="2011-12-19 14:26:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.12299714757388347" P_Q="1.0" P_Z="0.7579983577343975" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11977220327044333" TOTALS="YES" TOTAL_1="297" TOTAL_2="210" WEIGHT="100.00000000000001" Z="0.30811036136181">
<NAME>Deaths within 42 days</NAME>
<GROUP_LABEL_1>rHFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.697873835451746" CI_START="0.6589551202938655" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.4310216362742582" LOG_CI_START="-0.18114416305765832" LOG_EFFECT_SIZE="0.12493873660829992" MODIFIED="2011-01-04 18:06:24 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.359589220797146" STUDY_ID="STD-Bosch-2004" TOTAL_1="121" TOTAL_2="121" VAR="0.1293044077134986" WEIGHT="39.732679399021364"/>
<DICH_DATA CI_END="1.0646797969357618" CI_START="0.46596019241709097" EFFECT_SIZE="0.7043425324675324" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" LOG_CI_END="0.027219013095560955" LOG_CI_START="-0.33165118406547517" LOG_EFFECT_SIZE="-0.15221608548495708" MODIFIED="2011-03-04 20:19:02 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.21080213024851857" STUDY_ID="STD-Bosch-2008" TOTAL_1="176" TOTAL_2="89" VAR="0.044437538117313394" WEIGHT="60.26732060097865"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2011-12-19 14:26:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="1.0118124475310226" CI_END="1.0369662772809236" CI_START="0.8442744689762574" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9356731016213078" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="164" I2="1.1674542609005059" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.015764633121009678" LOG_CI_START="-0.07351634367760096" LOG_EFFECT_SIZE="-0.028875855278295653" METHOD="MH" MODIFIED="2011-12-19 14:24:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31446929939213875" P_Q="1.0" P_Z="0.20486600523261878" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="6.461301912621613E-5" TOTALS="YES" TOTAL_1="297" TOTAL_2="210" WEIGHT="100.0" Z="1.2678095244390508">
<NAME>Overall incidence by patients</NAME>
<GROUP_LABEL_1>rHuFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0278970866541455" CI_START="0.7606094666466408" EFFECT_SIZE="0.8842105263157894" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="95" LOG_CI_END="0.011949635149950465" LOG_CI_START="-0.11883827360388265" LOG_EFFECT_SIZE="-0.05344431922696612" MODIFIED="2010-08-05 22:12:41 +0200" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.0768254650125912" STUDY_ID="STD-Bosch-2004" TOTAL_1="121" TOTAL_2="121" VAR="0.005902152074400875" WEIGHT="46.09503296368761"/>
<DICH_DATA CI_END="1.1286216401973228" CI_START="0.8545111220561642" EFFECT_SIZE="0.9820487483530962" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="69" LOG_CI_END="0.052548373178558455" LOG_CI_START="-0.06828228026192794" LOG_EFFECT_SIZE="-0.007866953541684719" MODIFIED="2010-08-05 22:13:59 +0200" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.07097652395232264" STUDY_ID="STD-Bosch-2008" TOTAL_1="176" TOTAL_2="89" VAR="0.005037666952354629" WEIGHT="53.904967036312385"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11630664007167105" CI_END="1.1125898072276448" CI_START="0.7452668429480307" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.910591177822795" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="123" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.04633507691968773" LOG_CI_START="-0.12768820017727558" LOG_EFFECT_SIZE="-0.04067656162879389" METHOD="MH" MODIFIED="2011-12-19 14:25:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7330753312214275" P_Q="1.0" P_Z="0.359534699962171" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="590" TOTAL_2="443" WEIGHT="100.0" Z="0.9162520915284061">
<NAME>Serious adverse events by total adverse events</NAME>
<GROUP_LABEL_1>rHuFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2993422250281474" CI_START="0.6938067214306376" EFFECT_SIZE="0.9494695198705269" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="67" LOG_CI_END="0.1137235520481738" LOG_CI_START="-0.15876149713435003" LOG_EFFECT_SIZE="-0.022518972543088094" MODIFIED="2011-01-04 18:47:50 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.16005906671256148" STUDY_ID="STD-Bosch-2004" TOTAL_1="249" TOTAL_2="288" VAR="0.025618904836896203" WEIGHT="40.78771058705974"/>
<DICH_DATA CI_END="1.1478682570371157" CI_START="0.681929587656462" EFFECT_SIZE="0.8847402597402597" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="56" LOG_CI_END="0.05989204614119322" LOG_CI_START="-0.16626046591675933" LOG_EFFECT_SIZE="-0.05318420988778303" MODIFIED="2011-03-04 20:19:02 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.13284310505583066" STUDY_ID="STD-Bosch-2008" TOTAL_1="341" TOTAL_2="155" VAR="0.01764729056087446" WEIGHT="59.21228941294025"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.36646688234149094" CI_END="1.5950772077427715" CI_START="0.3966167780566464" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7953831673391951" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.20278170939014162" LOG_CI_START="-0.40162891780773646" LOG_EFFECT_SIZE="-0.09942360420879742" METHOD="MH" MODIFIED="2011-12-19 14:26:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5449367099238942" P_Q="1.0" P_Z="0.5190467319462205" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="297" TOTAL_2="210" WEIGHT="100.00000000000001" Z="0.6448155432535453">
<NAME>Thromboembolic adverse events by patients</NAME>
<GROUP_LABEL_1>rHuFVIIa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rHFVIIa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.764582443413702" CI_START="0.3617182777031607" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.44162954568939183" LOG_CI_START="-0.44162954568939183" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-01-04 18:47:09 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.5188307624789138" STUDY_ID="STD-Bosch-2004" TOTAL_1="121" TOTAL_2="121" VAR="0.26918536009445104" WEIGHT="46.82609598405319"/>
<DICH_DATA CI_END="1.6883145764883665" CI_START="0.2503745872962724" EFFECT_SIZE="0.6501623376623377" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.2274533700766267" LOG_CI_START="-0.6014097535649646" LOG_EFFECT_SIZE="-0.18697819174416896" MODIFIED="2010-11-13 13:59:23 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.48687830176570407" STUDY_ID="STD-Bosch-2008" TOTAL_1="176" TOTAL_2="89" VAR="0.237050480730256" WEIGHT="53.173904015946825"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-02-14 14:04:38 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-16 16:07:36 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flowchart of the search results (WHO: World Health Organization; CHBG: Cochrane Hepato-Biliary Group; RCT: randomised controlled trial) <BR/>
</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt0AAAIwCAYAAABa7deuAAAmz0lEQVR42u3d266jSBJA0fr/n+5R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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-02-14 14:04:38 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2012-02-14 14:04:38 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAS0AAAGRCAIAAAC/iXK3AAAQOElEQVR42u3dv65cRRLH8SuREDhw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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 1 realtive risk reduction of 80%.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2012-02-14 13:57:36 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The heterogeneity-corrected required information size (HCRIS) of 889 patients has been calculated based upon a proportion of patients dying within five days of 7.3% in the control group; a RRR of 80% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 57%. The cumulative Z score reaches the futility area (the two outward bending red curves), demonstrating that if you only want to introduce rHuFVIIa on the market with such large effect, then there is no need to conduct further trials.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 2 relative risk reduction 60%.jpg" FILE_TYPE="JPG" ID="FIG-05" MODIFIED="2012-02-14 13:57:43 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The heterogeneity-corrected required information size (HCRIS) of 1830 patients has been calculated based upon a proportion of patients dying within five days of 7.3% in the control group; a relative risk reduction of 60% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 57%. The cumulative Z score does not reach the futility area (which is not even drawn by the program), demonstrating that if you want to introduce rHuFVIIa on the market with such an intervention effect, then further randomised trials are needed.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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=
</FILE>
</FIGURE>
<FIGURE FILENAME="40%.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2012-02-14 13:57:55 +0100" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The heterogeneity-corrected required information size (HCRIS) of 4668 patients has been calculated based upon a proportion of patients dying within five days of 7.3% in the control group; a RRR of 40% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 57%. The cumulative Z score does not reach the futility area (which is not even drawn by the program), demonstrating that if you want to introduce rHuFVIIa on the market with such an intervention effect, then further randomised trials are needed.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAYAAABfdxm0AACAAElEQVR42uy9B7xV1Zn+n998/tOS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</FILE>
</FIGURE>
<FIGURE FILENAME="Figure 4 relative risk reduction 30%.jpg" FILE_TYPE="JPG" ID="FIG-07" MODIFIED="2012-02-14 13:57:49 +0100" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>The heterogeneity-corrected required information size (HCRIS) of 8784 patients has been calculated based upon a proportion of patients dying within five days of 7.3% in the control group; a RRR of 30% in the experimental intervention group; an alpha (&#945;) of 5%; a beta (&#946;) of 20%; and a diversity of 57%. The cumulative Z score does not reach the futility area (which is not even drawn by the program), demonstrating that if you want to introduce rHuFVIIa on the market with such an intervention effect, then further randomised trials are needed.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-02-14 14:04:35 +0100" MODIFIED_BY="[Empty name]">Search strategies (updated from 2005 to 20 December 2011</TITLE>
<APPENDIX_BODY MODIFIED="2012-01-14 20:11:11 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Name of database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time span</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Hepato-Biliary<BR/>Group Controlled<BR/>Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>December 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(('upper gastrointestinal' or digestive) and (bleeding or h*emorrhage)) AND (('human recombinant factor' OR 'recombinant blood factor' OR 'coagulation factor') and (VIIa OR 7a))</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cochrane Central Register of<BR/>Controlled Trials Register<BR/>(CENTRAL) in<BR/>
<I>The Cochrane Library</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 4, 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Gastrointestinal Hemorrhage explode all trees in MeSH products</P>
<P>#2 (upper gastrointestinal or digestive) and (bleeding or h*emorrhage) in All Fields in all products</P>
<P>#3 (#1 OR #2)</P>
<P>#4 MeSH descriptor Factor VIIaexplode all trees in MeSH products</P>
<P>#5 human recombinant factor and (VIIa or 7a)<B> </B>in All Fields in all products</P>
<P>#6 recombinant blood factor and (VIIa or 7a)in All Fields in all products</P>
<P>#7 coagulation factor and (VIIa or 7a)in All Fields in all products</P>
<P>#8 (#4 OR #5 OR #6 OR #7)</P>
<P>#9 (#3 AND #8)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1948 to December 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Gastrointestinal Hemorrhage/</P>
<P>2. ((upper gastrointestinal or digestive) and (bleeding or h*emorrhage)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>3. 1 or 2</P>
<P>4. exp Factor VII/</P>
<P>5. (human recombinant factor and (VIIa or 7a)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>6. (recombinant blood factor and (VIIa or 7a)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>7. (coagulation factor and (VIIa or 7a)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>8. 4 or 5 or 6 or 7</P>
<P>9. 3 and 8</P>
<P>10. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>11. 9 and 10<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to December 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp upper gastrointestinal bleeding/</P>
<P>2. exp gastrointestinal hemorrhage/</P>
<P>3. exp digestive system hemorrhage/</P>
<P>4. ((upper gastrointestinal or digestive) and (bleeding or h*emorrhage)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>5. 1 or 2 or 3 or 4</P>
<P>6. exp recombinant blood clotting factor 7a/</P>
<P>7. (human recombinant factor and (VIIa or 7a)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>8. (recombinant blood factor and (VIIa or 7a)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>9. 6 or 7 or 8</P>
<P>10. 5 and 9</P>
<P>11. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>12. 10 and 11<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (http://apps.isiknowledge.com)<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to December 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 3 #2 AND #1</P>
<P># 2 TS=(('human recombinant factor' OR 'recombinant blood factor' OR 'coagulation factor') and (VIIa OR 7a))</P>
<P># 1 TS=((upper gastrointestinal or digestive) and (bleeding or h*emorrhage))<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1982 to December 2011</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>"human recombinant$" OR rHuFVIIa OR FVIIa [Words] and cirrhosis OR upper gastrointestinal bleeding [Words] and clinical trial OR random$ OR placebo OR control OR trials OR trial OR clinicals trials [Words]</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 2 (3 references). &lt;br&gt;(&lt;a link_type=&quot;STUDY&quot; href=&quot;Bosch 2004&quot; protected=&quot;true&quot;&gt;Bosch 2004&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Bosch 2008&quot; protected=&quot;true&quot;&gt;Bosch 2008&lt;/a&gt;).&lt;/p&gt;&lt;p&gt;Included studies into meta-analysis: 2 (&lt;a link_type=&quot;STUDY&quot; href=&quot;Bosch 2004&quot; protected=&quot;true&quot;&gt;Bosch 2004&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Bosch 2008&quot; protected=&quot;true&quot;&gt;Bosch 2008&lt;/a&gt;).&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="255">
<FLOWCHARTBOX TEXT="&lt;p&gt;Potential studies: 14 references.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="240">
<FLOWCHARTBOX TEXT="&lt;p&gt;CENTRAL: 11 references.&lt;br&gt;MEDLINE: 21 references.&lt;br&gt;EMBASE: 167 references.&lt;br&gt;LILACS: 0 references.&lt;br&gt;CHBG Trial register: 11 references.&lt;br&gt;ISI Web Knowledge: 21 references.&lt;br&gt;WHO Ongoing Trials search portal: 0 references.&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Total: 232 references.&lt;/b&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;" WIDTH="315">
<OUT TEXT="&lt;p&gt;&lt;b&gt;Excluded studies:&lt;/b&gt;&lt;br&gt;Irrelevant/Non-RCT/narrative review: 218 references.&lt;/p&gt;" WIDTH="338"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;&lt;b&gt;Excluded&lt;/b&gt;: 11 references.&lt;/p&gt;&lt;p&gt;Reasons:&lt;br&gt;Case series: 2&lt;br&gt;Case report: 1&lt;br&gt;Descriptive study: 1&lt;br&gt;Review: 6&lt;br&gt;Systematic review: 1&lt;br&gt;&lt;/p&gt;" WIDTH="275"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>